Meet the Founder

Professor Zhu Yizhun

Founder and Chair of the Board

“One of China’s most accomplished returnee scientists”

— Science

“A pioneer of innovative drug research in China”

— Chemical & Engineering News (C&EN), American Chemical Society

Member, European Academy of Sciences and Arts (2023)
Ministry of Education Changjiang Distinguished Professor (2011)
Recipient, National Science Fund for Distinguished Young Scholars (2008)

ScholarGPS: Top 0.5% Scholars Worldwide
Stanford University: World’s Top 2% Scientists

A Distinguished Academic Journey

1983-1989

School of Medicine, Shanghai Jiao Tong University
Six-year Bachelor of Medicine (Clinical Medicine)

1990-1998

Heidelberg University, Germany
Ph.D. and Postdoctoral Research

1998-2015

Yong Loo Lin School of Medicine, National University of Singapore, Lee Kuan Yew
Research Fellow; Associate Professor; Professor (Adjunct)

2005-2016

Served nearly 10 years as Dean of the School of Pharmacy, Fudan University; Distinguished Young Scholar, Changjiang Scholar, 973 Program Chief Scientist, and Chief Scientist of the Major New Drug Innovation Program

2016–Present

Vice President, Macau University of Science and Technology; Founding Dean of the Faculty of Pharmacy
Chair Professor; Registered General Practitioner at MUST Hospital

Distinguished Research Achievements

Editorial Leadership

Served as Editor-in-Chief of Clinical Medication in China (1st edition) commissioned by China’s National Health Commission, and of Pharmacology, a national planned textbook (7th and 8th editions, plus 1st English edition). Also holds Editor-in-Chief positions for over 10 biomedical journals across China, the US, the UK, and other countries.

Publications

Has published 500+ papers to date, with 20,000+ citations in the Web of Science Core Collection and an H-index of 67.

Translation & Commercialization

Led the discovery and development of 20 first-in-class drug candidates, including Leonurine Sulfate (SCM-198) and S-Propargyl-Cysteine (ZYZ-802). In 2016, SCM-198 was successfully transferred for RMB 150 million, marking a landmark case of drug-asset translation in China.

Intellectual Property

The team’s R&D achievements include 38 granted invention patents in China, as well as 10+ drug invention patents in the United States and globally (PCT) and in Japan.